[HTML][HTML] Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease …
K Matsumoto, T Shiroyama, T Kuge… - Translational Lung …, 2022 - ncbi.nlm.nih.gov
Background There is no clear consensus regarding the safety and efficacy of immune
checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC) …
checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC) …
Immunotherapy use in patients with lung cancer and comorbidities
MS Von Itzstein, AS Gonugunta, HG Mayo… - The Cancer …, 2020 - journals.lww.com
Immune checkpoint inhibitor (ICI) therapy is now in widespread clinical use for the treatment
of lung cancer. Although patients with autoimmune disease and other comorbidities were …
of lung cancer. Although patients with autoimmune disease and other comorbidities were …
Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post‐marketing surveillance
H Uhara, T Tsuchida, Y Kiyohara… - The Journal of …, 2022 - Wiley Online Library
Nivolumab, a monoclonal antibody against human programmed death 1, was approved for
the treatment of melanoma in July 2014 in Japan. Because the Japanese phase II studies …
the treatment of melanoma in July 2014 in Japan. Because the Japanese phase II studies …
Pre-existing interstitial lung abnormalities are independent risk factors for interstitial lung disease during durvalumab treatment after chemoradiotherapy in patients …
W Daido, T Masuda, N Imano, N Matsumoto, K Hamai… - Cancers, 2022 - mdpi.com
Simple Summary Interstitial lung disease (ILD) is a life-threatening toxicity caused by
chemoradiotherapy and durvalumab; however, the risk factors for ILD during durvalumab …
chemoradiotherapy and durvalumab; however, the risk factors for ILD during durvalumab …
Interstitial lung abnormalities: new insights between theory and clinical practice
RE Ledda, G Milanese, F Milone, L Leo, M Balbi… - Insights into …, 2022 - Springer
Interstitial lung abnormalities (ILAs) represent radiologic abnormalities incidentally detected
on chest computed tomography (CT) examination, potentially related to interstitial lung …
on chest computed tomography (CT) examination, potentially related to interstitial lung …
Practice patterns in reporting interstitial lung abnormality at a tertiary academic medical center
JG Escalon, AJ Podolanczuk, KI Aronson, AC Legasto… - Clinical Imaging, 2023 - Elsevier
Purpose Interstitial lung abnormality (ILA) is a common finding on chest CTs and is
associated with higher all-cause mortality. The 2020 Fleischner Society position paper …
associated with higher all-cause mortality. The 2020 Fleischner Society position paper …
Coexistence of emphysema with non-small-cell lung cancer predicts the therapeutic efficacy of immune checkpoint inhibitors
Y Takayama, T Nakamura, Y Fukushiro, S Mishima… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: Chronic obstructive pulmonary disease coexisting with non-small-cell lung
cancer (NSCLC) was reported to be associated with a longer progression-free survival …
cancer (NSCLC) was reported to be associated with a longer progression-free survival …
Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non–Small-Cell Lung Cancer
M Petranovic, S McDermott, S Mercaldo, BP Little… - Clinical Lung Cancer, 2023 - Elsevier
Abstract Introduction/Background Immune-related pneumonitis is a potentially fatal
complication of treatment with immune checkpoint inhibitors (ICIs). Interstitial lung disease …
complication of treatment with immune checkpoint inhibitors (ICIs). Interstitial lung disease …
Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis
T Sugimoto, D Fujimoto, Y Sato, M Tamiya, T Yokoi… - Lung Cancer, 2022 - Elsevier
Objective Durvalumab was safe and effective in patients with unresectable stage III non-
small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT) in a phase 3 …
small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT) in a phase 3 …
Association of pre-existing lung interstitial changes with immune-related pneumonitis in patients with non-small lung cancer receiving immunotherapy
X Chen, Z Li, X Wang, J Zhou, Q Wei, R Jiang - Supportive Care in Cancer, 2022 - Springer
Background and aim Many pieces of literature have evaluated the predictive value of pre-
existing lung interstitial changes for immunotherapy-related pneumonia in patients with non …
existing lung interstitial changes for immunotherapy-related pneumonia in patients with non …